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Background: Persons with cystic fibrosis (CF) who tend to be hospitalized have poorer overall survival and quality of life. Whether differences
exist in hospitalization rates between males and females with CF is unknown. The objective was to assess sex-specific differences in
hospitalization rates after adjusting for clinically important factors within a universal health care system.
Methods: A provincial-based longitudinal study using national CF registry data linked to health administrative databases examined differences in
annual hospitalization rates estimated by Poisson regression using generalized estimating equations with adjustment for markers of CF disease
severity.
Results: Among those aged 7 to 19 years, the RR of respiratory-related annual hospitalizations among females vs. males was 1.38 (95%CI 1.11–1.73).
Among those over 19 years, the corresponding RR was 1.30 (95% CI 1.06–1.59).
Conclusions: Females affected by CF are at a higher risk of respiratory-related hospitalization, which may extend beyond classic clinical measures
of disease severity.
© 2010 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Sex differences; Hospitalizations1. Introduction
Among persons with cystic fibrosis (CF), hospitalizations for
pulmonary exacerbations are associated with poorer overall
survival, health-related quality of life, neurocognitive function
and sleep, while contributing to higher health care costs [1–6].
Hospitalizations also expose CF patients to antibiotic-resistant
bacteria [7]. About 35% of US patients with CF are hospitalized☆ Preliminary results of this study were presented at the North American
Cystic Fibrosis Conference in Anaheim October 3–6, 2007 and in Orlando,
October 23–25, 2008.
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doi:10.1016/j.jcf.2010.10.005each year, associated with advancing age, poorer pulmonary
function and, possibly, female sex [8,9]. However, prior studies
were restricted to adults with CF who harboured multi-drug
resistant bacteria [1], or were done in areas with private health
coverage [8,9], potentially limiting the generalizability of their
results. Furthermore, registries that depend on self-reported data
may not account for all aspects of health care utilization [10], or
may underestimate the total number of hospitalizations. No
study has systematically captured predictors of hospitalization
in CF patients using a combination of health administrative data
and clinical registry data, particularly while adjusting for
clinically important factors.
We evaluated whether sex-specific differences in hospital-
ization rates exist within a large cohort of pediatric and adult CF
patients, cared for under a universal health care system.d by Elsevier B.V. All rights reserved.
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2.1. General design
We completed a retrospective longitudinal cohort study of
CF patients across the Province of Ontario, Canada.
2.2. Data sources
The Canadian CF Patient Data Registry (CPDR) contains
detailed clinical information on all CF patients receiving clinical
care, including 10 CF centres in Ontario. The CPDR contains
annual records for each participant on demographic and clinical
variables, including height, weight, lung function, sputum
bacteriology (reported as any positive culture in a given year),
pancreatic status and CF-related co-morbidities. Nutritional
markers and lung function are recorded from the first clinic visit
of the year while other variables captured within the registry are
determined throughout the year.
Linked administrative health care databases, housed at the
Institute for Clinical Evaluative Sciences (ICES), were used for
this study. The databases include the Canadian Institute for
Health Information Discharge Abstracts Database (CIHI-DAD),
which describes all hospital admissions; the Registered Persons
Database (RPDB), which describes demographics and vital
statistics; the Ontario Home Care Administrative System
(OHCAS) Database, which describes home care services
delivered; and the Ontario Health Insurance Plan (OHIP)
Database, which describes physician billing for inpatient and
outpatient services. Until 2002, up to 16 discharge diagnoses
according to the International Classification of Disease, Ninth
Revision (ICD-9) were used to characterize hospital admissions
within CIHI-DAD.
The Ontario-specific CPDR was probabilistically linked to the
RPDB by patient name, date of birth and sex, using AutoMatch
software [11]. Resulting linkages were then completed determin-
istically, using an encrypted version of the patient'sOHIPnumber,
common to all administrative databases.
2.3. Study cohort
All CF patients aged 7 years and older were retrospectively
identified between the years 1993 and 2002. In order to account
for partial years, an offset variable was created representing the
number of days that year an individual was eligible for the study
outcome. Details on the creation of the study cohort are
described in Fig. 1.
2.4. Study exposure, covariates and outcome
Data for each participant included sex, date of CF diagnosis,
date of death, date of transplant, pancreatic status (determined by
the use of pancreatic enzymes), pulmonary function, height,
weight, CF-related complications and sputum bacteriology. The
Wang and Hankinson pulmonary function equations for children
and adults were used to calculate the predicted norms for forced
expiratory volume in 1 s (FEV1), in litres [12,13]. The percentpredicted FEV1 was calculated as follows: (measured FEV1/
predicted FEV1)×100. For those over the age of 19 years, body
mass index (BMI) was expressed in kg/m2. Because BMI in
children and adolescents varies with age and sex, Centres for
Disease Control (CDC) growth charts were used to calculate age-
and sex-adjusted Z-score BMI for those aged 7 to 19 years [14].
Once a subject received a transplant, subsequent data was
excluded from the analysis. Multiple imputation was used to
estimate missing clinical values [15].
The primary exposure of interest was a participant's sex. The
primary study outcome was the annual number of respiratory-
related hospital admissions. Respiratory-related hospital admis-
sions were identified for each subject using any ICD-9
diagnosis code related to the respiratory system that was
identified in CIHI-DAD as being the most responsible
diagnosis. Of the 110 potential codes related to respiratory
disease, 65 were deemed as potentially indicative of a
respiratory-related CF admission; the most common was “cystic
fibrosis”, accounting for 78% of the hospital admissions
documented herein. In addition, courses of home intravenous
(IV) antibiotic therapy following a hospital admission or started
directly from the outpatient clinic setting were included as
hospitalizations. The initiation of home IV antibiotic therapy
was defined as a hospital admission of less than 3 days duration
with an associated home care claim within 1 week of discharge
with no homecare claims within the 4 weeks preceding the
hospitalization date. In order to capture home IV antibiotic
therapy initiated directly from the outpatient clinic, a clinic visit
was identified using physician claims within the OHIP
database, which captures all physician billing claims. If a
homecare claim was registered within 7 days of the clinic visit
date, with no homecare claims in the preceding 4 weeks, this
was assumed to represent an individual who was started on
home IV antibiotic therapy directly from clinic without a
hospital admission.
2.5. Sensitivity analyses
We performed separate sensitivity analyses to evaluate the
robustness of our findings. Firstly, the main analysis was carried
out excluding missing data, without using multiple imputation.
The algorithm used to identify home intravenous antibiotic
therapy has not been validated; therefore we analyzed the data
using only those respiratory-related hospitalizations identified
by an inpatient hospital stay as part of a second sensitivity
analysis.
2.6. Statistical analysis
Means (SD) were reported for continuous variables, and
proportions (%) reported for categorical variables. Unpaired t-
tests were used to compare continuous variables and the Chi-
squared test to compare categorical variables between males and
females. The risk of hospitalization between females vs. males
was estimated using Poisson regression and generalized
estimating equations (GEE), which accounts for repeated
measures [16], with adjustment for other covariates, as listed
Fig. 1. Creation of study cohort.
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confidence intervals (CI) for respiratory-related hospitalizations
between females vs. males were further stratified according to
markers of CF-related disease severity, chosen a priori.
Because of inherent age-related differences in CF severity and
measures of lung function, all analyses were separately performed
in children aged 7 to 19 years and adults aged 20 years and older.
Over- and under-dispersion of the data was evaluated by
comparing the Poisson and negative binomial distributions, and
the goodness of fit of the models. The zero-inflated Poisson
regression model was also used to examine whether the data
consisted of an excessive number of participants having zero
hospitalizations. Linearity of continuous variables was assessed
using a quadratic term and/or categorization to assess for a
threshold effect.
A two-sided P-value b0.05 was set for statistical significance.
All analyses were done using SAS 9.1 statistical software.
The research study received ethics approval from the
Research Ethics Board of Sunnybrook Health Sciences Centre.
Prior to 2002, individual patient consent was not required forregistries. At the time the Registry data was requested for this
study, only data to the end of 2002 were available for release.
3. Results
Of 1580 CPDR participants identified as being followed in
Ontario, 1464 (93%) were successfully linked to the adminis-
trative databases, of which 1174 participants were aged 7 years
and older, and 45% were female (Fig. 1). Forty-three percent of
the cohort was followed for the entire 10-year period, and 74%
were followed for 5 years or more. No significant differences
were noted in follow-up time between males and females. The
most recent clinical measurements performed on each partic-
ipant are listed in Table 1.
3.1. Hospitalizations
3.1.1. All participants
Among the 1174 participants, there were 6194 hospitalizations
(all cause), of which 4931 (80%) were inpatient hospitalizations
Table 1
Characteristics of study participants according to their last recorded clinical measurements.
Age group (years)
7–19 Over 19
Females
(n=366)
Males
(n=420)
Females
(n=274)
Males
(n=355)
Mean (SD) age, years 14.7 (4.1) 14.9 (4.1) 30.6 (9.0) 31.0 (7.9)
Mean (SD) age at diagnosis, years 2.1 (3.6) 2.1 (3.5) 7.8 (11.7) 6.3 (9.6)
Mean (SD) % predicted FEV1 71.9 (26.3) 72.8 (25.9) 51.7 (23.4) 50.3 (24.3)
Mean (SD) BMI a −0.27 (1.0)* −0.46 (1.2)* 21.8 (4.1)* 22.7 (3.6)*
Percent pancreatic insufficient 90.2 91.4 77.4 82.3
Percent diabetes mellitus 12.8† 4.3† 29.2† 16.3†
Percent Pseudomonas aeruginosa bacteriology 73.5 73.6 77.7 71.0
Percent Burkholderia cepacia bacteriology 10.9 13.6 28.5* 36.1*
*pb0.05; †pb0.001 noted for differences between males and females for each age category; Chi-squared test was used for dichotomous covariates and Student's t-test
for continuous covariates.
a Z-scores were used for those aged 7–19 years, and kg/m2 for those aged 20 years and over.
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hospitalizations, 3676 (75%) were coded as respiratory-related.
Fifty-eight percent of all participants had 1 or more respiratory-
related hospitalizations over the study period, ranging from 0 to 15
hospitalizations per year. Therewas no evidence of under- or over-
dispersion (dispersion factor=0.94), and the dataset did not have
an excessive number of zero-count hospitalizations.No significant
sex interactions were identified.
3.1.2. Participants aged 7–19 years
A total of 786 young participants contributed 4408 person-
years of observation. The absolute difference in the annual rate
of hospitalizations was higher in females than males, equivalent
to an adjusted RR of 1.37 (95% CI 1.10–1.71) (Table 2).
3.1.3. Participants aged 20 years and older
A total of 629 adult participants contributed 4036 person-
years of observation. The adjusted RR of respiratory-related
hospitalization comparing females vs. males was 1.30 (95% CI
1.06–1.59) (Table 2).
3.1.4. Stratified analysis
In both young and adult CF patients, the increased RR of
respiratory-related hospitalizations among females was consis-Table 2
Risk of annual hospitalizations for respiratory-related causes comparing females and
Age group Total number of respiratory
hospitalizations over the
10-year study period
Annual respi
hospitalizatio
respiratory-re
per 100 patie
Females Males Females
7 to 19 years 807 678 45.1
≥20 years 1136 1055 77.3
a The models were adjusted for age (continuous in years), FEV1 (continuous in
mildN60; moderate 40–60; severeb40 [aged≥20 years]), body mass index (continuo
status (insufficient vs. sufficient), diabetes mellitus (present vs. absent), Pseudomon
subject became positive they were coded as such for subsequent years] (present vs. a
aged ≥20 years, the model was also adjusted for the number of outpatient clinic vistently seen across the majority of markers of CF disease severity
(Fig. 2).
4. Discussion
We observed a higher risk of respiratory-related hospitaliza-
tions among adolescent and adult females with CF. This was so
even after adjusting for clinically important covariates,
suggesting that this phenomenon cannot be fully explained by
traditional markers of CF disease severity. Furthermore, the
higher risk in females was noted across several clinical sub-
groups and the results of sensitivity analyses were consistent
with this finding (data not shown).
Important strengths of this study include its large population-
based sample of 1174 children and adults with CF, its
longitudinal design, and the combined use of administrative
and patient-level data. Moreover, we adjusted for traditional
markers of CF disease severity. As a limitation, respiratory-
related hospitalizations were defined by an ICD-9 code that
described the most responsible diagnosis after admission, based
on an algorithm that has not been formally validated. This may
have introduced some error, in that some admissions were
incorrectly attributed to respiratory complications. At the same
time, we do not see why this would be biased for females overmales.
ratory
n rate for
lated causes
nt-years
Rate ratio of annual respiratory
hospitalizations comparing
females vs. males
Males Crude Adjusted a
32.0 1.46 (1.11–1.91) 1.37 (1.10–1.71)
51.3 1.45 (1.16–1.82) 1.30 (1.06–1.59)
percent predicted [aged 7–19 years]) and categorical (FEV1 percent predicted:
us z-score [aged 7–19 years] or continuous kg/m2 [aged≥20 years]), pancreatic
as aeruginosa or Burkholderia cepacia sputum bacteriology positivity [once a
bsent), age at diagnosis (continuous), and birth year (continuous). Among those
its per year.
Fig. 2. Risk of hospitalization for respiratory illness in association with female vs. male sex, stratified by markers of disease severity.
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and each admission was considered as equivalent to another,
such that males may have had fewer hospitalizations per year
but a longer LOS. Missing clinical data, the accuracy of non-
missing data, and the strategies used to deal with missing data
could potentially have biased the study findings, but sex was
unambiguously recorded for all study participants. Other
literature suggests that multiple imputation strategies provide
unbiased estimates, even if the missingness is not completely at
random [17,18]. A sensitivity analysis excluding missing data
showed higher respiratory-related hospitalization rates in
females suggesting that the results are robust (data not
shown). Finally, the study cohort excluded individuals youngerthan 7 years of age and hospitalizations occurring after
transplantation therefore our results may not be generalizable
to these specific groups.
In contrast to others [1,8,9], the current study's primary
focus was on sex-specific differences in respiratory-related
hospitalization rates among a broad population of individuals
with CF. Previous cross-sectional studies were descriptive in
nature, lacking rigorous statistical methods to quantify
associated risks [8,9]. In addition, earlier work failed to specify
the reason for hospitalization. The only Canadian study
included adults with multi-drug resistant bacteria, a small sub-
group of the overall CF population [1]. Despite studying this
specific group of individuals with CF, they too found that
98 A. Stephenson et al. / Journal of Cystic Fibrosis 10 (2011) 93–99female sex was a significant predictor of future hospital
admissions for pulmonary exacerbations [1].
Sex differences in CF outcomes outside of the hospital
setting have been previously reported, but the reasons why this
is so remain elusive. Several studies have documented worse
overall survival in female CF patients despite similar disease
severity to males [19,20]. CF-related diabetes mellitus is more
common in women than men [21], and females with diabetes
tend to die earlier than affected males [22]. Finally, studies have
shown that females are diagnosed with CF at a later age than are
males [23].
Sex-based differences in disease activity and disease severity
may be attributed to sociological, behavioural, hormonal or
genetic factors. One sociological factor relates to “ambulatory
care sensitive conditions”, in which a disease or its complication
is sub-optimally managed in the outpatient setting, and is thus
dealt with through an avoidable hospitalization [24]. Though a
progressive genetic disease for which there is no cure,
medications such as inhaled tobramycin [25], mucolytic therapy
[26] and chronic oral azithromycin [27] have been shown to
reduce the need for hospitalization and intravenous antibiotic
therapy for pulmonary exacerbations in CF. The gender gap in
hospitalization rates seen in our study could be a result of
differential prescribing patterns for medications in this patient
population, a variable not captured herein. Female sex
hormones may modulate the symptomatology and severity of
CF lung disease [28], and worsening of respiratory symptoms
during menstruation has been described [29]. Coakley et al.
postulated that high estrogen levels reduce the regulation of
airway surface liquid volume homeostasis, resulting in
decreased mucociliary clearance [30]. It is possible that
hormonal differences between males and females contribute
to differential hospitalization rates seen in our study and future
work in this area is needed to understand the role hormones play
in symptomatology in CF. Finally, hyperglycemia impairs the
ability to fight infection and a higher proportion of females had
diabetes in our study. It is possible that females had worse
diabetic control contributing to increased respiratory hospital-
ization rates; however, this is unlikely to be the sole reason as
the overall proportion of persons with diabetes in our study
population, particularly the younger age group, was relatively
low. Despite this, the impact of diabetic control on respiratory
hospitalizations in CF is an interesting area for future research.
The decision to hospitalize a patient may be influenced by
what is communicated to the health care provider. For example,
Hawker et al. showed that, despite their equal willingness to
undergo joint replacement surgery, women were less likely to
discuss the option of surgery with their physician, resulting in
less frequent recommendations for surgery when indicated [31].
Whether the opposite is true in CF, in which females are more
likely to be admitted to hospital, is not known.
5. Conclusions
Using a national clinical registry linked to administrative
databases, our research has shown that sex differences in
hospitalization rates exist in pediatric and adult CF patients,even after adjusting for markers of disease severity. Future
research is needed to elucidate why these differences may exist,
such that targeted interventions could be introduced to narrow
this gender gap. Research evaluating differences in outpatient
management, communication strategies between patients and
health care providers and hormonal influences could shed light
on this matter.
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